GeneOne Life Science, Inc. (011000.KS)
KRW 2035.0
(-3.1%)
KRW 2035.0
(-3.1%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 151 Billion KRW | -32.24% |
| 2022 | 222.86 Billion KRW | -10.67% |
| 2021 | 249.49 Billion KRW | 82.69% |
| 2020 | 136.57 Billion KRW | 166.99% |
| 2019 | 51.15 Billion KRW | 3.77% |
| 2018 | 49.29 Billion KRW | 8.02% |
| 2017 | 45.63 Billion KRW | -30.5% |
| 2016 | 65.66 Billion KRW | 37.68% |
| 2015 | 47.69 Billion KRW | 16.99% |
| 2014 | 40.76 Billion KRW | 28.11% |
| 2013 | 31.82 Billion KRW | -20.37% |
| 2012 | 39.96 Billion KRW | -1.24% |
| 2011 | 40.46 Billion KRW | 1.02% |
| 2010 | 40.05 Billion KRW | -32.16% |
| 2009 | 59.04 Billion KRW | 53.64% |
| 2008 | 38.42 Billion KRW | -11.32% |
| 2007 | 43.33 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 151.94 Billion KRW | 0.62% |
| 2024 Q2 | 150.6 Billion KRW | -0.88% |
| 2023 Q1 | 219.45 Billion KRW | -1.53% |
| 2023 Q2 | 198.47 Billion KRW | -9.56% |
| 2023 FY | 151 Billion KRW | -32.24% |
| 2023 Q3 | 191.39 Billion KRW | -3.56% |
| 2023 Q4 | 151 Billion KRW | -21.1% |
| 2022 Q1 | 245.08 Billion KRW | -1.77% |
| 2022 Q3 | 259.9 Billion KRW | 3.0% |
| 2022 Q4 | 222.86 Billion KRW | -14.25% |
| 2022 FY | 222.86 Billion KRW | -10.67% |
| 2022 Q2 | 252.33 Billion KRW | 2.96% |
| 2021 FY | 249.49 Billion KRW | 82.69% |
| 2021 Q1 | 135.99 Billion KRW | -0.42% |
| 2021 Q2 | 136.45 Billion KRW | 0.34% |
| 2021 Q3 | 139.37 Billion KRW | 2.14% |
| 2021 Q4 | 249.49 Billion KRW | 79.0% |
| 2020 FY | 136.57 Billion KRW | 166.99% |
| 2020 Q2 | 57.06 Billion KRW | -1.63% |
| 2020 Q3 | 120.88 Billion KRW | 111.82% |
| 2020 Q4 | 136.57 Billion KRW | 12.98% |
| 2020 Q1 | 58.01 Billion KRW | 13.42% |
| 2019 Q1 | 54.45 Billion KRW | 10.46% |
| 2019 FY | 51.15 Billion KRW | 3.77% |
| 2019 Q3 | 55.93 Billion KRW | 3.89% |
| 2019 Q2 | 53.83 Billion KRW | -1.13% |
| 2019 Q4 | 51.15 Billion KRW | -8.55% |
| 2018 Q3 | 50.78 Billion KRW | -5.83% |
| 2018 Q4 | 49.29 Billion KRW | -2.93% |
| 2018 Q2 | 53.93 Billion KRW | 23.82% |
| 2018 Q1 | 43.55 Billion KRW | -4.56% |
| 2018 FY | 49.29 Billion KRW | 8.02% |
| 2017 FY | 45.63 Billion KRW | -30.5% |
| 2017 Q4 | 45.63 Billion KRW | -17.08% |
| 2017 Q3 | 55.03 Billion KRW | -2.76% |
| 2017 Q2 | 56.6 Billion KRW | -8.31% |
| 2017 Q1 | 61.73 Billion KRW | -5.98% |
| 2016 Q2 | 73.17 Billion KRW | 47.69% |
| 2016 FY | 65.66 Billion KRW | 37.68% |
| 2016 Q4 | 65.66 Billion KRW | -3.49% |
| 2016 Q3 | 68.03 Billion KRW | -7.03% |
| 2016 Q1 | 49.54 Billion KRW | 3.9% |
| 2015 FY | 47.69 Billion KRW | 16.99% |
| 2015 Q4 | 47.69 Billion KRW | 2.07% |
| 2015 Q3 | 46.72 Billion KRW | 7.78% |
| 2015 Q2 | 43.34 Billion KRW | 3.2% |
| 2015 Q1 | 42 Billion KRW | 3.04% |
| 2014 Q3 | 31.06 Billion KRW | 1.73% |
| 2014 Q2 | 30.53 Billion KRW | -2.79% |
| 2014 Q1 | 31.41 Billion KRW | -1.28% |
| 2014 FY | 40.76 Billion KRW | 28.11% |
| 2014 Q4 | 40.76 Billion KRW | 31.22% |
| 2013 FY | 31.82 Billion KRW | -20.37% |
| 2013 Q4 | 31.82 Billion KRW | 6.14% |
| 2013 Q3 | 29.97 Billion KRW | -3.11% |
| 2013 Q2 | 30.94 Billion KRW | -5.44% |
| 2013 Q1 | 32.72 Billion KRW | -18.11% |
| 2012 Q4 | 39.96 Billion KRW | 0.0% |
| 2012 FY | 39.96 Billion KRW | -1.24% |
| 2012 Q1 | 48.97 Billion KRW | 0.0% |
| 2011 FY | 40.46 Billion KRW | 1.02% |
| 2011 Q3 | 42.18 Billion KRW | 17.88% |
| 2011 Q2 | 35.78 Billion KRW | -4.95% |
| 2011 Q1 | 37.65 Billion KRW | 0.0% |
| 2010 Q1 | 60.64 Billion KRW | 0.0% |
| 2010 FY | 40.05 Billion KRW | -32.16% |
| 2010 Q3 | 43.02 Billion KRW | -26.91% |
| 2010 Q2 | 58.86 Billion KRW | -2.94% |
| 2009 FY | 59.04 Billion KRW | 53.64% |
| 2009 Q3 | 58.77 Billion KRW | 55.19% |
| 2009 Q2 | 37.87 Billion KRW | -17.88% |
| 2009 Q1 | 46.12 Billion KRW | 20.02% |
| 2008 Q1 | 40.86 Billion KRW | -5.7% |
| 2008 Q2 | 41 Billion KRW | 0.34% |
| 2008 Q3 | 40.78 Billion KRW | -0.54% |
| 2008 Q4 | 38.42 Billion KRW | -5.77% |
| 2008 FY | 38.42 Billion KRW | -11.32% |
| 2007 Q2 | 41.19 Billion KRW | -2.05% |
| 2007 FY | 43.33 Billion KRW | 0.0% |
| 2007 Q4 | 43.33 Billion KRW | 6.23% |
| 2007 Q3 | 40.79 Billion KRW | -0.99% |
| 2007 Q1 | 42.06 Billion KRW | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ORIENT BIO Inc. | 96.98 Billion KRW | -55.698% |
| Green Cross Holdings Corporation | 3737.7 Billion KRW | 95.96% |
| Green Cross Holdings Corporation | 2643.31 Billion KRW | 94.287% |
| Pharmicell Co., Ltd. | 99.19 Billion KRW | -52.239% |
| Green Cross Corporation | 2643.31 Billion KRW | 94.287% |
| Celltrion, Inc. | 19917.53 Billion KRW | 99.242% |
| Samsung Biologics Co.,Ltd. | 16046.19 Billion KRW | 99.059% |
| SK bioscience Co.,Ltd. | 1852.43 Billion KRW | 91.848% |
| SK Biopharmaceuticals Co., Ltd. | 723.17 Billion KRW | 79.119% |
| Prestige BioPharma Limited | 711.72 Billion KRW | 78.783% |